A BIOINFORMATIC ANALYSIS OF THE AORTIC VALVE STENOSIS TRANSCRIPTOME REVEALS CHANCES OF ROSUVASTATIN TREATMENT

NUÑEZ PEDROZO, CRISTIAN; BELMONTE, MARTINA; PERALTA, TOMÁS; IMPERATORI, MARIANA; CUNIBERTI LUIS; PORTO, MARTINA; GIUNTA, GUSTAVO

Helsinki

Congreso; European Atherosclerosis Society (EAS) 89th; 2021

Sociedad Europea de Aterosclerosis

There is epidemiological evidence that associates cardiovascular risk factors with aortic valve stenosis (AVS). The drug treatment of choice are beta-blockers and ACE inhibitors, although there is a constant demand to optimize it. On the basis of the recently published transcriptomes on the progression of AVS, we proposed a bioinformatic analysis to identify vacant molecular targets and treatment timing for rosuvastatin. The transcriptomes were retrieved from the CICS database of Brigham and Women?s hospital and represented different stages of disease progression: nondiseased, fibrotic and calcific. Differential gene expression analysis was performed employing OmicsBox using the EdgeR package with FDR correction ≤ 0.05, P value ≤ 0.05, logFC  1. The raw counts were normalized with the TMM method. Genes related to beta-blockers, ACEi and Rosuvastatin were retrieved from GeneCards and intersected with the differentially expressed genes using Venn Diagrams. The tool PathfindR was used to perform enrichment analysis (Fold Enrichment; p-value) on the intersected genes. The intersection analysis for the fibrotic stage showed PPAR (FE: 77.12; p: 0.011) and JAK-STAT* (FE: 17.93; p: 0.0001), whereas the calcific stage revealed Fluid shear stress and angiogenesis (FE: 15.04; p: